Pfizer (PFE) said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed positive results.
The study met its primary endpoint, with tilrekimig showing a statistically significant increase in participants who saw a 75% or higher reduction in the eczema area and severity, across all doses tested, compared to placebo.
Tilrekimig is a potentially first-in-class, once-a-month antibody targeting multiple chronic Type 2 inflammatory conditions, including atopic dermatitis, asthma, and chronic obstructive pulmonary disease.
Pfizer (PFE) plans to accelerate tilrekimig to Phase 3 development, with a pivotal study in atopic dermatitis set to start within 2026.
“We are encouraged by the topline Phase 2 results for tilrekimig, which show that combining the potent inhibition of IL-4/13 and TSLP pathways has the potential to deliver improved efficacy over the standard of care for atopic dermatitis,” said Mike Vincent, Chief Inflammation & Immunology Officer at Pfizer. “We plan to advance a broad clinical development program for tilrekimig, a potential first-in-class trispecific antibody discovered at Pfizer, in atopic dermatitis and other Th2-mediated inflammatory diseases including asthma and COPD.”
The Phase 2 study has two ongoing stages: one with participants who previously received biologic treatments and receiving either tilrekimig or placebo, and another with participants receiving either ompekimig or placebo.
Pfizer is also studying tilrekimig in a Phase 2 study in asthma and recently started a Phase 2b/3 study of the drug candidate in COPD.